Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(83.3%)

Phase 1

1(16.7%)

6Total

Phase 2(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02998450Phase 1Completed

A Study of IMR-687 in Healthy Adult Volunteers

Role: collaborator

NCT03401112Phase 2Completed

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Role: collaborator

NCT04474314Phase 2Terminated

A Study of IMR-687 in Subjects With Sickle Cell Disease

Role: collaborator

NCT05312021Phase 2Withdrawn

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

Role: collaborator

NCT04411082Phase 2Terminated

A Study of IMR-687 in Subjects With Beta Thalassemia

Role: collaborator

NCT04053803Phase 2Active Not Recruiting

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

Role: lead

All 6 trials loaded